Wed, Apr 16, 2014, 5:36 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Dendreon Corp. Message Board

  • investsmarty investsmarty May 31, 2013 10:05 AM Flag

    DNDN announced positive data today and presenting at a conference next week

    Data from an open-label study demonstrate the presence of existing immunological memory in advanced prostate cancer patients retreated with PROVENGE several years after initial treatment for androgen dependent prostate cancer (ADPC) in the Phase III PROTECT study. In addition, the retreatment appeared to boost product potency compared with prior treatment. Separately, data from two Phase II studies indicate that PROVENGE can be combined with androgen deprivation therapy (ADT) or abiraterone acetate plus prednisone.
    “These studies help us understand how PROVENGE may be combined or sequenced with other advanced prostate cancer treatments,” said Mark Frohlich, M.D., executive vice president of research and development and chief medical officer at Dendreon. “We are also pleased with the preliminary data demonstrating that the antigen-presenting cell activity of DN24-02 for HER2+ urothelial cancer is similar to that of PROVENGE. The data highlight the promise of our active cellular immunotherapy platform and furthers Dendreon’s position as a leader in personalized cancer therapies.”

    Conference Details:
    Dendreon Corporation (NASDAQ: DNDN) announced today that four abstracts featuring PROVENGE® (sipuleucel-T) data from ongoing Phase II sequencing studies and the PROCEED registry, and two abstracts highlighting preliminary Phase II data of DN24-02, an investigational active cellular immunotherapy in patients with surgically resected HER2+ urothelial cancer, will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013 in Chicago, IL.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Superb.

      The science speaks for itself.

      DNDN is a marathon run to save lives and improve quality of life.

      DNDN is about the FUTURE for patients and the future of medicine.

      From a technical standpoint, the picture continues to improve, and does reflect the positives expressed by the science.

      High volume buying today. Nice 'minute' bowl formation and forming of handle for another move higher. We gapped up above the midpoint of the Bollinger Band and close to resistance area. Slight pullback for more buying to crush resistance at last. Glad I added several time at recent lows. jmo

      Peace Patients Patience Wisdom Joy Agape ~

2.690.00(0.00%)Apr 16 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.